Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dipeptidyl peptidase 1 (DPPI), also known as cathepsin C, is a lysosomal cysteine protease that plays a key role in the activation of granule-associated serine proteases in immune and inflammatory cells. It catalyzes the removal of N-terminal dipeptides from polypeptides, leading to the maturation and activation of enzymes like granzymes and neutrophil serine proteases. DPPI deficiency is associated with impaired immune function and inflammatory disorders, making it a potential therapeutic target for modulating excessive neutrophil activity.
Inhibition of DPPI to modulate neutrophil activity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dipeptidyl Peptidase 1 (DPPI).